Open AccessHow well are biologic and conventional DMARDs tolerated in psoriatic arthritis: A real world study
Author(s) -
Issrah Jawad,
AUTHOR_ID,
Muhammed K. Nisar,
AUTHOR_ID
Publication year - 2022
Publication title -
european journal of rheumatology
Language(s) - English
Resource type - Journals
eISSN - 2147-9720
pISSN - 2148-4279
DOI - 10.5152/eurjrheum.2021.21027
Subject(s) - medicine , tolerability , psoriatic arthritis , discontinuation , retrospective cohort study , ustekinumab , arthritis , adverse effect , adalimumab , disease
Even though disease-modifying antirheumatic drugs (DMARDs) are well established in rou- tine clinical practice, longitudinal real-world data for their retention and tolerability are sparse, espe- cially in psoriatic arthritis (PsA) patients. Our objective was to describe the characteristics of our large PsA cohort including the comorbidities and evaluate real-world DMARD tolerability and discontinua- tion rates with reasons for stopping treatment.